Early versus delayed administration of intravenous magnesium sulfate for pediatric asthma

Area of Science:

• Pediatric Emergency Medicine
• Respiratory Medicine
• Clinical Pharmacology

Background:

• Asthma exacerbations are a common reason for pediatric emergency department (ED) visits.
• Intravenous magnesium sulfate (IV Mg) is a potential adjunctive therapy for severe asthma exacerbations.
• Timely administration of therapies is crucial for improving outcomes in pediatric asthma.

Purpose of the Study:

• To describe and examine factors associated with early administration of IV Mg in children with asthma exacerbations.
• To evaluate the impact of early IV Mg on the delivery of other asthma medications.
• To assess the safety and effectiveness of early IV Mg in terms of ED throughput and patient return visits.

Main Methods:

• Retrospective cohort study of children aged 5-11 years treated for asthma exacerbation in a pediatric ED.
• Defined 'early administration' as IV Mg given within 60 minutes of ED triage.
• Compared clinical management, therapies, and outcomes between early and delayed IV Mg groups.

Main Results:

• Early IV Mg was associated with more timely administration of bronchodilators and systemic corticosteroids.
• No significant differences were observed in 72-hour return ED visits or 1-week readmissions between groups.
• Hypoxia, respiratory rate, retractions, and prior asthma-related hospitalizations were associated with early IV Mg administration.

Conclusions:

• Early IV Mg administration in pediatric asthma exacerbations is safe and effective.
• It facilitates more timely delivery of first-line asthma therapies.
• Early IV Mg improves ED throughput without adversely affecting return visits or hospitalizations.